Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 1, pp 147–152 | Cite as

Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin

  • Han Ying Bao
  • Wei Jia Fang
  • Xiao Chen Zhang
  • Gen Ming Shi
  • Sui Huang
  • Lan Fang Yu
  • Jin Chen
  • Hai Bo Mou
  • Jing Deng
  • Peng Shen
  • Nong XuEmail author
Original Article

Abstract

Purpose

To evaluate the efficacy and safety of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.

Methods

The FOLFIRI regimen consisted of intravenous infusion of irinotecan 180 mg/m2 on day 1 plus leucovorin (LV) 400 mg/m2 on day 1 plus 5-fluorouracil (5-FU) 400 mg/m2 bolus on day 1 plus 46-hour intravenous infusion of 5-FU 2,400 mg/m2, every 2 weeks as one cycle. The main selection criterion for this study was the advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.

Results

Of the 57 evaluable patients for efficacy, 4 (7.5%) had a partial response, 36 (67.9%) had stable disease, and 13 (24.5%) had progressive disease. Median progression-free survival was 4.8 months (95% CI 3.9–5.7 months), and median overall survival was 7.8 months (95% CI 13.1–16.5 months). Safety analysis was based on the data of 57 evaluable patients. The most frequently observed grade 3 or 4 toxicities were neutropenia 16 (27.8%), nausea/vomiting 7 (12.3%), and diarrhea 1 (1.8%).

Conclusion

FOLFIRI regimen is effective and well tolerated in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin in Chinese population.

Keywords

FOLFIRI Metastatic colorectal cancer Irinotecan Second-line chemotherapy 

References

  1. 1.
    Jemal A, Thomas A, Murray T et al (2002) Cancer statistics. CA Cancer J Clin 52:23–47CrossRefPubMedGoogle Scholar
  2. 2.
    Ling Yang, Liandi Li, Yude CAen et al (2005) Cancer incidence and mortality estimates and prediction for year 2000 an d 2005 in China. Chin J Health Stat 22:218–221Google Scholar
  3. 3.
    de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMedGoogle Scholar
  4. 4.
    Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047CrossRefPubMedGoogle Scholar
  5. 5.
    Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMedGoogle Scholar
  6. 6.
    Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905–914CrossRefPubMedGoogle Scholar
  7. 7.
    Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMedGoogle Scholar
  8. 8.
    Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418CrossRefPubMedGoogle Scholar
  9. 9.
    Rougier P, Van Cutsem E, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407–1412CrossRefPubMedGoogle Scholar
  10. 10.
    Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMedGoogle Scholar
  11. 11.
    Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319CrossRefPubMedGoogle Scholar
  12. 12.
    Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 10:896–903Google Scholar
  13. 13.
    de Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808–815PubMedGoogle Scholar
  14. 14.
    Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25:4779–4786CrossRefPubMedGoogle Scholar
  15. 15.
    Folprecht G, Seymour MT, Saltz L et al (2008) Irinotecan/Fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2, 691 patients in randomized controlled trials. J Clin Oncol 26:1443–1451CrossRefPubMedGoogle Scholar
  16. 16.
    Mabro M, Artru P, Andre T et al (2006) A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 94:1287–1292CrossRefPubMedGoogle Scholar
  17. 17.
    Wang Y, Xu JM, Shen L et al (2007) Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients. Zhonghua Zhong Liu Za Zhi 29:913–916PubMedGoogle Scholar
  18. 18.
    Canal P, Gay C, Dezeuze A et al (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14:2688–2695PubMedGoogle Scholar
  19. 19.
    Bidard FC, Tournigand C, André T (2009) Efficacy of FOLFIRI-3 (irinotecan D1, D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol 20:1042–1047CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Han Ying Bao
    • 1
  • Wei Jia Fang
    • 1
  • Xiao Chen Zhang
    • 1
  • Gen Ming Shi
    • 1
  • Sui Huang
    • 1
  • Lan Fang Yu
    • 1
  • Jin Chen
    • 1
  • Hai Bo Mou
    • 1
  • Jing Deng
    • 1
  • Peng Shen
    • 1
  • Nong Xu
    • 1
    Email author
  1. 1.Department of Medical Oncology, The First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations